News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>CMSI: 3 Reasons for Recent Underperformance of Pharma Sector vs HSI; Top Picks INNOVENT BIO/ HANSOH PHARMA/ KEYMED BIO-B
Since May, the Hang Seng Biotech Index has underperformed the HSI by about 1,300 bps, becoming the biggest laggard sector and marking the industry’s entry into a downturn pha...
Reset
Send
The window will close in 5 seconds
<Research>CMSI: 3 Reasons for Recent Underperformance of Pharma Sector vs HSI; Top Picks INNOVENT BIO/ HANSOH PHARMA/ KEYMED BIO-B
Close
Recommend
18
Positive
21
Negative
15
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

Since May, the Hang Seng Biotech Index has underperformed the HSI by about 1,300 bps, becoming the biggest laggard sector and marking the industry’s entry into a downturn phase, CMSI said in its report. The broker summarized three reasons for the evident recent underperformance of Hong Kong-listed pharma/biotech stocks: liquidity constraints, rising policy uncertainty over overseas BD cooperation, and valuation markdowns for certain clinical assets.

On the macro level, amid increasing market polarization, liquidity has continued to flow into AI-related themes, driving strong outperformance in those sectors, while other sectors have experienced notable valuation compression. Meanwhile, overseas BD deals for China’s innovative drugs are facing heightened policy uncertainty.

Related NewsCiti: Market Overreacts to Potential Biopharma Tech Export Restrictions, Creating Buy Opportunities
John Moolenaar, the Chairman of the House Select Committee on the Strategic Competition Between the United States and the Chinese Communist Party, proposed including biotechnology-related technologies in the COINS Act to restrict cross-border intellectual property licensing. He specifically noted that multinational pharmaceutical companies, including Bristol Myers Squibb, have recently stepped up out-licensing and co-development partnerships with Chinese companies.

The broker believed that recent macro disturbances and sector volatility provide a good opportunity for long-term investors to accumulate leading high-quality Chinese biopharmaceutical companies at lower levels. Its top picks were INNOVENT BIO (01801.HK)  +0.200 (+0.262%)    Short selling $414.90M; Ratio 35.508%   , HANSOH PHARMA (03692.HK)  -0.480 (-1.611%)    Short selling $203.43M; Ratio 33.128%   and KEYMED BIO-B (02162.HK)  -0.650 (-1.101%)    Short selling $14.79M; Ratio 6.987%   . It was also watchful of AKESO (09926.HK)  -5.850 (-5.882%)    Short selling $315.46M; Ratio 16.768%   and HENGRUI PHARMA (01276.HK)  +1.150 (+2.156%)    Short selling $27.06M; Ratio 8.843%   , which are not yet under its coverage.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-05 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.